We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock
ARDS

Delisted

ARDS was delisted on the 18th of July, 2023.

Back to rankings

6 hedge funds and large institutions have $556K invested in Aridis Pharmaceuticals Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

35% more capital invested

Capital invested by funds: $411K → $556K (+$145K)

0% more funds holding

Funds holding: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$19.1K
2
Victory Capital Management
Victory Capital Management
Texas
+$13.2K
3
BlackRock
BlackRock
New York
+$3.63K
4
Wells Fargo
Wells Fargo
California
+$242

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$6.65K
2
UBS Group
UBS Group
Switzerland
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$429K – – –
Millennium Management
2
Millennium Management
New York
$60K -$6.65K -1,043 -9%
BlackRock
3
BlackRock
New York
$36K +$3.63K +570 +10%
Bank of America
4
Bank of America
North Carolina
$17K +$19.1K +3,001 +60,020%
Victory Capital Management
5
Victory Capital Management
Texas
$12K +$13.2K +2,068 New
Wells Fargo
6
Wells Fargo
California
$2K +$242 +38 +13%
UBS Group
7
UBS Group
Switzerland
– -$3K -734 Closed

ARDS Hedge Fund Activity: Q1 2020 in Review

6 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q1 2020, worth a combined $556K — up 35% from $411K a quarter earlier.

Fund positioning in ARDS was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Bank of America, adding an estimated $19.1K. The largest seller was Millennium Management, cutting an estimated $6.65K.

  • 6 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q1 2020, unchanged from Q4 2019.
  • Funds reported $556K of Aridis Pharmaceuticals Inc. Common Stock stock for Q1 2020, up 35% quarter-over-quarter.
  • 1 fund opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q1 2020 and 1 closed out, a net change of 0 holders.
  • The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q1 2020 was Bank of America, an estimated $19.1K added.
  • The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q1 2020 was Millennium Management, an estimated $6.65K sold.

Based on aggregated 13F filings for Q1 2020.